Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 8, 2010, Pages 3770-3775

  Serruto, Davide ^a   Spadafina, Tiziana ^a,f   Ciucchi, Laura ^a   Lewis, Lisa A ^b   Ram, Sanjay ^b   Tontini, Marta ^a   Santini, Laura ^a   Biolchi, Alessia ^a   Seib, Kate L ^a   Giuliani, Marzia M ^a   Donnelly, John J ^a   Berti, Francesco ^a   Savino, Silvana ^a   Scarselli, Maria ^a   Costantino, Paolo ^a   Simon Kroll, J ^c   O'Dwyer, Clíona ^c   Qiu, Jiazhou ^d   Plaut, Andrew G ^d   Moxon, Richard ^e   Rappuoli, Rino ^a   Pizza, Mariagrazia ^a   Aricò, Beatrice ^a   more..

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d Center for Clinical and Translational Research   (United States)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Arg rich region; Lactoferrin; NalP; Serum resistance; Vaccine

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; GNA2132 ANTIGEN; HEPARIN; HEPARIN BINDING PROTEIN; LACTOFERRIN; NEISSERIAL HEPARIN BINDING ANTIGEN; OUTER MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIUM IDENTIFICATION; IMMUNITY; IMMUNOGENICITY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION;

AMINO ACID SEQUENCE; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD PROTEINS; CARRIER PROTEINS; HUMANS; LACTOFERRIN; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; VIRULENCE FACTORS;

ANIMALIA; BACTERIA (MICROORGANISMS); NEISSERIA MENINGITIDIS;

EID: 77649265923     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0915162107     Document Type: Article

References (37)

1. Stephens DS, Greenwood B, Brandtzaeg P (2007) Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369:2196-2210.
2. Borrow R, et al. (2006) Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 24:5093-5107.
3. Stephens DS (2007) Conquering the meningococcus. FEMS Microbiol Rev 31:3-14.
4. Pizza M, et al. (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287:1816-1820.
5. Giuliani MM, et al. (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 103:10834-10839.
6. Welsch JA, et al. (2003) Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 188:1730-1740.
7. Plested JS, Granoff DM (2008) Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin Vaccine Immunol 15:799-804.
8. Plested JS, Welsch JA, Granoff DM (2009) Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin Vaccine Immunol 16:785-791.
9. Rostand KS, Esko JD (1997) Microbial adherence to and invasion through proteoglycans. Infect Immun 65:1-8.
10. Schneider MC, et al. (2006) Functional significance of factor H binding to Neisseria meningitidis. J Immunol 176:7566-7575.
11. Madico G, et al. (2006) The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177:501-510.
12. Chen T, Swanson J, Wilson J, Belland RJ (1995) Heparin protects Opa+ Neisseria gonorrhoeae from the bactericidal action of normal human serum. Infect Immun 63: 1790-1795.
13. Turner DP, Wooldridge KG, Ala'Aldeen DA (2002) Autotransported serine protease A of Neisseria meningitidis: an immunogenic, surface-exposed outer membrane, and secreted protein. Infect Immun 70:4447-4461.
14. van Ulsen P, et al. (2003) A Neisserial autotransporter NalP modulating the processing of other autotransporters. Mol Microbiol 50:1017-1030.
15. Hendrixson DR, et al. (2003) Human milk lactoferrin is a serine protease that cleaves Haemophilus surface proteins at arginine-rich sites. Mol Microbiol 47:607-617.
16. Qiu J, et al. (1998) Human milk lactoferrin inactivates two putative colonization factors expressed by Haemophilus influenzae. Proc Natl Acad Sci USA 95:12641-12646.
17. Bambini S, et al. (2009) Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27:2794-2803.
18. Jacobsson S, et al. (2009) Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 27:1579-1584.
19. Jacobsson S, et al. (2006) Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine 24:2161-2168.
20. Lucidarme J, et al. (2009) Characterisation of fHbp, nhba (gna2132), nadA, porA, Sequence Type and the genomic presence of IS1301 in group B meningococcal ST269 clonal complex case-isolates from England and Wales. J Clin Microbiol.
21. Rabenstein DL (2002) Heparin and heparan sulfate: structure and function. Nat Prod Rep 19:312-331.
22. Jackson RL, Busch SJ, Cardin AD (1991) Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 71:481-539.
23. de Vries FP, Cole R, Dankert J, Frosch M, van Putten JP (1998) Neisseria meningitidis producing the Opc adhesin binds epithelial cell proteoglycan receptors. Mol Microbiol 27:1203-1212.
24. Menozzi FD, et al. (1996) Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med 184:993-1001.
25. Hannah JH,Menozzi FD,Renauld G, Locht C, BrennanMJ(1994) Sulfated glycoconjugate receptors for the Bordetella pertussis adhesin filamentous hemagglutinin (FHA) and mapping of the heparin-binding domain on FHA. Infect Immun 62:5010-5019.
26. Rappuoli R, et al. (1992) Progress towards the development of new vaccines against whooping cough. Vaccine 10:1027-1032.
27. Duensing TD, Wing JS, van Putten JP (1999) Sulfated polysaccharide- directed recruitment of mammalian host proteins: a novel strategy in microbial pathogenesis. InfectImmun 67: 4463-4468.
28. Menozzi FD, et al. (2002) Enhanced bacterial virulence through exploitation of host glycosaminoglycans. Mol Microbiol 43:1379-1386.
29. Claus H, Maiden MC, Maag R, Frosch M, Vogel U (2002) Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology 148: 1813-1819.
30. Deghmane AE, et al. (2000) Intimate adhesion of Neisseria meningitidis to human epithelial cells is under the control of the crgA gene, a novel LysR-type transcriptional regulator. EMBO J 19:1068-1078.
31. Hammerschmidt S, et al. (1996) CapsulephasevariationinNeisseriameningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease. Mol Microbiol 20: 1211-1220.
32. Von Loewenich FD, Wintermeyer E, Dümig M, Frosch M (2001) Analysis of transcriptional control mechanisms of capsule expression in Neisseria meningitidis. Int J Med Microbiol 291:361-369.
33. Pangburn MK, Atkinson MA, Meri S (1991) Localization of the heparin-binding site on complement factor H. J Biol Chem 266:16847-16853.
34. Sahu A, Pangburn MK (1993) Identification of multiple sites of interaction between heparin and the complement system. Mol Immunol 30:679-684.
35. Yu H, Muñoz EM, Edens RE, Linhardt RJ (2005) Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance. Biochim Biophys Acta 1726:168-176.
36. Lo H, Tang CM, Exley RM (2009) Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis 9: 418-427.
37. Borrow R, et al. (2005) Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol 12:970-976.